Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation

Area of Science:

• Hematology
• Immunology
• Pulmonology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) survival has improved, increasing the incidence of long-term toxic effects.
• Chronic graft-vs-host disease (cGVHD) is a significant long-term complication, with lung involvement leading to bronchiolitis obliterans syndrome (BOS).

Observation:

• Bronchiolitis obliterans syndrome (BOS) affects up to 6% of HSCT recipients, with a dismal 5-year survival rate of only 13%.
• Survival statistics for BOS have remained stagnant for over two decades.

Findings:

• Diagnosis of BOS is often delayed, and limited understanding of its pathogenesis hinders therapeutic advancements.
• Current diagnostic criteria for BOS are being critically evaluated.

Implications:

• Early recognition of BOS is essential for timely therapeutic intervention before irreversible airway damage occurs.
• Further research into BOS pathogenesis and improved diagnostic strategies are needed to enhance HSCT patient outcomes.